GlassScriptPhysician profile
Scott M Kelly
NPI 1366556557
$4,061.37
in general payments reported to CMS, 2019-2025
32 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $227 · 2021: $164 · 2022: $464 · 2023: $900 · 2024: $727 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $607.93 | 2019-2025 | |
| Abbvie INC. | $512.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $508.62 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $414.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.13 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $168.73 | 2019-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $153.23 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $142.24 | 2019-2023 | |
| Lilly USA, LLC | $106.95 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $96.09 | 2020-2025 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $95.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $89.87 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $89.11 | 2019-2022 | |
| Axsome Therapeutics, INC. | $86.88 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $72.51 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72.27 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.06 | 2021-2025 | Jascayd |
| Gilead Sciences, INC. | $60.85 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $52.15 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.09 | 2025 | Caplyta |
| Philips North America LLC | $49.53 | 2025 | Lm Undivided |
| Esperion Therapeutics, INC. | $48.20 | 2024 | Nexletol |
| Abbott Laboratories | $38.78 | 2025 | Proclaim, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $35.93 | 2019 | |
| Medtronic, INC. | $32.90 | 2023 | Synchromedii, Intellis Adaptivestim |
| Eisai INC. | $21.45 | 2025 | |
| Exact Sciences Corporation | $17.11 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $16.45 | 2021 | |
| Boston Scientific Corporation | $16.04 | 2025 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2020 | |
| Genentech USA, INC. | $14.27 | 2019 | |
| Shield Therapeutics INC | $14.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.